A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: the European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial Solange Peters , Sarah Danson , Baktiar Hasan , Urania Dafni , Niels Reinmuth , Margarita Majem , Kurt G. Tournoy , Michael T. Mark , Miklos Pless , Manuel Cobo , Delvys Rodriguez-Abreu , Lionel Falchero , Teresa Moran , Ana Laura Ortega Granados , Isabelle Monnet , Katja Mohorcic , Bartomeu Massuti Sureda , Daniel Betticher , Ingel Demedts , Jose Antionio Macias , Sinead Cuffe , Andrea Luciani , Jose Garcia Sanchez , Alessandra Curioni-Fontecedro , Oliver Gautschi , Gillian Price , Linda Coate , Roger von Moos , Christoph Zielinski , Mariano Provencio , Jessica Menis , Barbara Ruepp , Alessia Pochesci , Heidi Roschitzki-Voser , Benjamin Besse , Manuela Rabaglio , Mary E. R. O'Brien , Rolf A. Stahel Journal of Thoracic Oncology（2020）
Key words
NSCLC, RANK, RANKL, Denosumab, Bone metastases
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
